A prospective cohort tracking subclinical cardiac dysfunction in breast-cancer patients receiving anthracycline chemotherapy.
Get in Touch
Interested in collaborating with us or learning more about our research? We’d love to hear from you.
[EXAMPLE] Anthracycline Cardiotoxicity Surveillance Cohort
Study period 2023 to 2026
Funder Heart Foundation of Australia
Objectives
- Detect early subclinical left-ventricular dysfunction
- Validate strain-imaging thresholds for intervention
Methodology
Serial echocardiography with global longitudinal strain and serum biomarker sampling at baseline, mid- and post-treatment.